Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Functional Brands Inc. stock logo
MEHA
Functional Brands
$0.01
$0.09
$0.01
$8.00
$269KN/A25.71 million shs1.16 million shs
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
$0.50
$0.68
$0.50
$160.00
$205K0.01177,918 shsN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$0.17
$0.18
$0.10
$1.14
$751K1.254.07 million shs985,257 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.02
$0.02
$0.01
$1.86
$765K1.62332,624 shs74,845 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.00%-84.78%-94.06%-96.21%+629,900.00%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.00%0.00%0.00%0.00%-26.58%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
0.00%-5.98%-37.66%-1.98%-78.46%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.00%-5.56%+20.57%+70.00%-97.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Functional Brands Inc. stock logo
MEHA
Functional Brands
$0.01
$0.09
$0.01
$8.00
$269KN/A25.71 million shs1.16 million shs
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
$0.50
$0.68
$0.50
$160.00
$205K0.01177,918 shsN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$0.17
$0.18
$0.10
$1.14
$751K1.254.07 million shs985,257 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.02
$0.02
$0.01
$1.86
$765K1.62332,624 shs74,845 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.00%-84.78%-94.06%-96.21%+629,900.00%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.00%0.00%0.00%0.00%-26.58%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
0.00%-5.98%-37.66%-1.98%-78.46%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.00%-5.56%+20.57%+70.00%-97.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Functional Brands Inc. stock logo
MEHA
Functional Brands
1.00
SellN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.00
N/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
2.00
Hold$1.00478.03% Upside
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TCBP, WINT, MEHA, and VRAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2026
Functional Brands Inc. stock logo
MEHA
Functional Brands
UpgradeSell (E-)Sell (E)
4/8/2026
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
Reiterated RatingSell (E+)
(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Functional Brands Inc. stock logo
MEHA
Functional Brands
$6.67M0.04$0.02 per share0.27$0.09 per share0.07
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
$4.76M0.04N/AN/A$519.58 per share0.00
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$10K75.08N/AN/A$1.26 per share0.14
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$0.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Functional Brands Inc. stock logo
MEHA
Functional Brands
$760K-$0.32N/AN/AN/AN/AN/AN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
-$7.35MN/AN/AN/AN/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$6.06MN/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$8.77N/AN/AN/AN/A-207.34%-50.19%N/A

Latest TCBP, WINT, MEHA, and VRAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q1 2026
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/A-$0.36N/A-$0.36N/A$1.65 million
3/27/2026Q4 2025
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/A$0.01N/A$0.01N/A$1.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/AN/AN/AN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
N/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.25
1.20
0.64
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.67
1.12
N/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/A
11.37
11.22
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.43
0.25

Institutional Ownership

CompanyInstitutional Ownership
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
16.25%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
8.61%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
Functional Brands Inc. stock logo
MEHA
Functional Brands
4.26%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
15.44%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
45.10%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Functional Brands Inc. stock logo
MEHA
Functional Brands
3342.74 million40.92 millionN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
80410,00028,000Not Optionable
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
54.34 million2.38 millionNot Optionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
3044.99 million3.66 millionNot Optionable

Recent News About These Companies

Windtree Therapeutics Delays Quarterly Report Filing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Functional Brands stock logo

Functional Brands NASDAQ:MEHA

$0.0063 0.00 (0.00%)
As of 06/18/2026 03:59 PM Eastern

Our company operates in the nutraceutical supplement industry. We are a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, mental clarity & focus, sleep, prenatal and urinary. Our end markets focus on end-consumers through different channels that include pharmacies, US wholesalers, international distributors and direct-to-consumers sales. Our products are sold over the counter, and consumers do not need a prescription to purchase our products. Our products are not approved by the FDA. Our company also operates in the hemp industry as a retailer of hemp derived products in categories such as capsules, cigarettes, gummies, and tinctures with a commercial end market, and end-consumers. Our Products Kirkman Brand Our “Kirkman” brand products are manufactured in our FDA registered, cGMP certified facility in Lake Oswego, Oregon. Established in 1949, Kirkman specializes in manufacturing nutritional supplements and is one of the oldest companies dedicated to serving the special needs community. Our Kirkman brand offers more than 150 products, including probiotics, enzymes, vitamins, multivitamins, amino acids, antioxidants, immune support, essential fatty acids, preconception, prenatal supplements, personal care products and other specialty products. Kirkman treats patients with autism spectrum disorders and special dietary needs through an established network of over 2,000 doctors in over 40 countries. Our Kirkman brand operates in 95% of the major subsegments in the supplement industry. Kirkman has a long-standing loyal customer and consumer base due to the rigorous testing of products in compliance with FDA requirements. Kirkman has been endorsed by various businesses and celebrities, including the famous and original Shark Tank member, Kevin Harrington. Digestive enzymes: Over the counter oral digestive enzyme supplements are a combination of proteases, which aid protein digestion; lipases, which aid in fat digestion; and amylases, which aid in carbohydrate digestion. These may be prescribed by a doctor in some cases, when the pancreas does not make enough digestive enzymes on its own. People are increasingly taking over the counter (“OTC”) digestive enzymes in lower doses to support general gut health. Essential fatty acids: Also called omega-3 fatty acids, essential fatty acids are important digestive chemicals that the body cannot make on its own. Our products under the Kirkman Brand include, but are not limited to, the following: . Supplements for Autism; . Essential Fatty Acids; . Oxytocin; . Vitamin B12; . Vitamin B6 and Magnesium; . Glutathione; . Melatonin; . Functional Mushrooms; . Probiotics; . Multivitamins and Minerals; and . Digestive Enzymes; . Antioxidants. . Amino Acids; P2i (prenatal) Brand We launched a certified prenatal vitamin in April 2024 for expectant mothers under the P2i by Kirkman brand. These vitamins have been specially formulated by our company to provide essential nutrients for both the mother and the developing fetus. The International Federation of Gynecology and Obstetrics (“FIGO”) published a position statement about toxic chemicals and environmental contaminants in prenatal vitamins. FIGO’s recommendation from the October 2023 position statement highlights that patients should only consume, and clinicians should only prescribe, vitamins and supplements that have been independently assessed to make certain they do not contain contaminants. Manufacturers should be held to a standard of production that assures safety and minimizes contaminants and certification of all prenatal vitamins becomes the standard of care. The FIGO Committee report on Climate Change and Toxic Environmental Exposures brought together global scientists to review reputable reference sources for chemicals that have the potential to impact maternal and newborn health, including the USA Environmental Protection Agency, the European Union, and the California EPA. The group of experts recommended several approaches, including: 1. creating a list of toxic chemicals and contaminants that should be screened for in Prenatal Vitamins and reduced to de minimis standards; and 2. conducting assays of existing vitamins to assess ongoing risk to maternal and newborn health. This work can extend to personal exposure risk by offering women testing for the presence of potentially toxic environmental chemicals. Mass Spectrometry currently offers the most comprehensive measurement. This first publication of a list of toxic chemicals and contaminants represents the most comprehensive testing available at present but does not purport to identify or eliminate all potential sources of toxicity. We are currently the only certified prenatal vitamin in the market that aligns to the FIGO position statement. We have formulated and produced a prenatal vitamin called P2i by Kirkman. There are approximately 3.6 million pregnancies alone in the United States (https://www.cdc.gov/nchs/fastats/births.htm) and the initial market focus for this product will be the United States with the expectation to expand globally since FIGO’s position statement reaches all countries. The P2i by Kirkman prenatal vitamin has been certified by The FORUM, a nonprofit 501(c)(3) organization dedicated to promoting low-toxicity standards for prenatal healthy products. The FORUM operates under a Memorandum of Understanding (MOU) with FIGO, a globally recognized organization of obstetricians and gynecologists. This MOU establishes a shared objective to reduce environmental toxicity in prenatal products. . The certification process involves rigorous testing and evaluation to ensure compliance with The FORUM’s low-toxicity standards, which align with FIGO’s objectives for maternal and fetal health. These standards include: . Analysis of 24 Heavy Metals, ensuring levels are below stringent safety thresholds . Testing for the presence of 120 toxic chemicals, such as pesticides and endocrine disruptors, with strict limits to prevent potential harm . Utilization of ISO 17025-accredited laboratories for all testing to ensure reliability and reproducibility of results . Purity Labs, an ISO 17025-accredited laboratory, as directed by The FORUM, conducted testing, which confirmed the product’s compliance with The FORUM’s criteria. Based on this testing, The FORUM issued its certification, indicating that Kirkman’s prenatal vitamin meets its standards for low toxicity and safety. HempTown Naturals Brand All HempTown Naturals products are produced and sold in compliance with the US 2018 Farm Bill and the US Agricultural Act of 2014. Cannabidiol (“CBD”) and cannabigerol (“CBG”) are cannabinoids present in the cannabis plant. Both CBD and CBG are used in hemp derived products. These products are believed to help in treating certain neurodegenerative and inflammatory conditions(1). CBD CBD is the second most prevalent ingredient in cannabis. While CBD is an integral component of medical marijuana, it is derived directly from the hemp plant, both of which are the same species of Cannabis sativa L. One of the hundreds of components of Cannabis sativa L., CBD does not cause a “high” by itself. According to a report from the World Health Organization, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health related products associated with the use of pure CBD”(2). As reported by Forbes Health, CBD is applied topically or consumed through smoke inhalation or edible consumption. CBD interacts with neuroreceptors in your endocannabinoid system, which sends signals between your cells to help regulate your movement, mood, homeostasis, and immune system. Different studies have shown that CBD can offset everyday anxiety and depression(3). CBG CBG is another compound found in hemp which doesn’t have intoxicatingly psychoactive effects. CBG, often referred to by experts as “the mother of all cannabinoids,” is the cannabinoid from which other types of cannabinoids (including CBD) are derived, says Michelle Sexton, a naturopathic doctor who works at the Pain Trauma Institute in San Diego. “CBG is the first compound in the biosynthesis (the production of chemical compounds by a living organism) of the other cannabinoids,” she adds. CBG is available in many forms, including tinctures, gummies, capsules and topical creams and lotions. CBG is often coupled with CBD in these products because the two cannabinoids can provide complimentary benefits, such as decreasing inflammation and pain, says Fraser Smith, a naturopathic doctor, as well as assistant dean and associate professor at the National University of Health Services in Lombard, Illinois. CBD and CBG occur naturally in hemp extract which is the source of our cannabinoids(4). Golf Mellow Brand The Company has utilized existing product formulations with plans to introduce 12 different products under the Golf Mellow brand. A brand logo and packaging has been created to support the existing formulations. These supplements will be targeting the golf industry and golf professionals. These products include capsules, a powder, a cream and tinctures to help golfers of all levels improve their game and overall well-being. The capsules are packed with a blend of essential vitamins and minerals that support joint health, flexibility, and energy levels. The tinctures are made from all-natural ingredients and provide a quick and easy way to support focus and mental clarity, helping athletes stay in the zone and make the perfect shot. The creams are specially designed to provide targeted relief for sore muscles and joints, helping them stay comfortable and focused on the course. Some of these products include Sleep Caps to ensure that players are well rested the night before, Super B12 Powder which provides the energy needed for the perfect round, Calm Caps which help manage anxiety when players need it most, and Epsom Salt Cream & Recovery Caps, which aids with recovery. According to data from the National Golf Foundation 28.1 million people (aged six and over) played on a golf course in the United States in 2024 – furthermore there were another 19.1 million people who took part in off-course activities like driving ranges, indoor golf simulators or venues like Topgolf(5). We are currently incorporated and in good standing in the State of Delaware. Our registered address is in Lake Oswego, Oregon.

TC Biopharm stock logo

TC Biopharm NASDAQ:TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Virax Biolabs Group stock logo

Virax Biolabs Group NASDAQ:VRAX

$0.17 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$0.17 0.00 (-2.31%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.02 0.00 (0.00%)
As of 06/18/2026 03:45 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.